| Literature DB >> 35268740 |
Priyanka Maiti1, Priyanka Sharma2, Mahesha Nand3, Indra D Bhatt4, Muthannan Andavar Ramakrishnan5, Shalini Mathpal6, Tushar Joshi6, Ragini Pant6, Shafi Mahmud7, Jesus Simal-Gandara8, Sultan Alshehri9, Mohammed M Ghoneim10, Maha Alruwaily10, Ahmed Abdullah Al Awadh11, Mohammed Merae Alshahrani11, Subhash Chandra12.
Abstract
Among the various types of cancer, lung cancer is the second most-diagnosed cancer worldwide. The kinesin spindle protein, Eg5, is a vital protein behind bipolar mitotic spindle establishment and maintenance during mitosis. Eg5 has been reported to contribute to cancer cell migration and angiogenesis impairment and has no role in resting, non-dividing cells. Thus, it could be considered as a vital target against several cancers, such as renal cancer, lung cancer, urothelial carcinoma, prostate cancer, squamous cell carcinoma, etc. In recent years, fungal secondary metabolites from the Indian Himalayan Region (IHR) have been identified as an important lead source in the drug development pipeline. Therefore, the present study aims to identify potential mycotic secondary metabolites against the Eg5 protein by applying integrated machine learning, chemoinformatics based in silico-screening methods and molecular dynamic simulation targeting lung cancer. Initially, a library of 1830 mycotic secondary metabolites was screened by a predictive machine-learning model developed based on the random forest algorithm with high sensitivity (1) and an ROC area of 0.99. Further, 319 out of 1830 compounds screened with active potential by the model were evaluated for their drug-likeness properties by applying four filters simultaneously, viz., Lipinski's rule, CMC-50 like rule, Veber rule, and Ghose filter. A total of 13 compounds passed from all the above filters were considered for molecular docking, functional group analysis, and cell line cytotoxicity prediction. Finally, four hit mycotic secondary metabolites found in fungi from the IHR were screened viz., (-)-Cochlactone-A, Phelligridin C, Sterenin E, and Cyathusal A. All compounds have efficient binding potential with Eg5, containing functional groups like aromatic rings, rings, carboxylic acid esters, and carbonyl and with cell line cytotoxicity against lung cancer cell lines, namely, MCF-7, NCI-H226, NCI-H522, A549, and NCI H187. Further, the molecular dynamics simulation study confirms the docked complex rigidity and stability by exploring root mean square deviations, root mean square fluctuations, and radius of gyration analysis from 100 ns simulation trajectories. The screened compounds could be used further to develop effective drugs against lung and other types of cancer.Entities:
Keywords: Eg5; Indian Himalayan Region; fungi; lung cancer; machine learning; molecular docking; secondary metabolites
Mesh:
Year: 2022 PMID: 35268740 PMCID: PMC8911701 DOI: 10.3390/molecules27051639
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Statistical performance of different classifiers used for the development of screening model in the training set.
Comparison of performance of different classifiers for development of screening model in the training set.
| Classifier | Correctly Classified Instances % (Value) | Kappa Statistic | Mean Absolute Error | Root Mean Square Error | MCC | ROC Area |
|---|---|---|---|---|---|---|
| Random forest | 97.0588 | 0.9401 | 0.08 | 0.1731 | 0.942 | 0.989 |
| J48 | 96.7914 | 0.9346 | 0.05 | 0.175 | 0.937 | 0.964 |
| Decision stump | 96.7914 | 0.9346 | 0.06 | 0.175 | 0.937 | 0.947 |
| Random tree | 92.7807 | 0.8544 | 0.07 | 0.2687 | 0.855 | 0.928 |
| Bagging (REP tree) | 96.5241 | 0.9292 | 0.06 | 0.1844 | 0.931 | 0.96 |
Pharmacological indices of the screened ligands by Lipinski’s rule, CMC-50 like rule, Veber rule, and Ghose filter.
| Title * | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacological Indices | |||||||||||||
| MW | 358 | 358 | 372 | 372 | 330 | 346 | 378 | 378 | 380 | 364 | 386 | 370 | 358 |
| logp | 4 | 4 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 4 | 4 | 2 |
| Alogp | 1 | 1 | 1 | 1 | 0 | −1 | 1 | 1 | 0 | 1 | 3 | 3 | 0 |
| HBA | 5 | 5 | 6 | 6 | 7 | 8 | 6 | 6 | 8 | 7 | 7 | 6 | 7 |
| HBD | 2 | 2 | 3 | 3 | 2 | 3 | 4 | 4 | 4 | 3 | 4 | 3 | 3 |
| TPSA | 84 | 84 | 96 | 96 | 102 | 123 | 107 | 107 | 134 | 113 | 124 | 104 | 113 |
| AMR | 98 | 98 | 105 | 105 | 90 | 91 | 113 | 113 | 106 | 104 | 109 | 108 | 87 |
| nRB | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 6 | 6 | 5 |
| nAtom | 52 | 52 | 51 | 51 | 38 | 39 | 46 | 46 | 40 | 39 | 50 | 49 | 55 |
| nAcidicGroup | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| RC | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 |
| nRigidB | 26 | 26 | 25 | 25 | 23 | 24 | 28 | 28 | 29 | 28 | 23 | 22 | 21 |
| nAromRing | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 2 | 2 | 2 | 0 |
| nHB | 7 | 7 | 9 | 9 | 9 | 11 | 10 | 10 | 12 | 10 | 11 | 9 | 10 |
| SAlerts | 4 | 4 | 5 | 5 | 5 | 5 | 0 | 0 | 4 | 4 | 3 | 4 | 2 |
* Compound CID: 1-138970029, 2-139591442, 3-139590281, 4-139590280, 5-16737098, 6-16737097, 7-12085445, 8-54586497, 9-10339712, 10-10248188, 11-77461063, 12-77461065, and 13-10203477.
Figure 2(a) Drug-likeness filters used for screening compounds. (b,c) Active site prediction of Eg5 protein for molecular docking.
Figure 3(a) Binding free energy of the screened ligands through molecular docking. (b) Functional group frequency comparison between established inhibitors and screened compounds. (c) Binding insights of the screened ligand, Phelligridin-C, with Eg5 protein. (d) 2D structure of screened compound.
Interaction profile of screened ligands with Eg5 protein.
| Ligand Name | Hydrophobic Interactions | Hydrogen Bond | Other | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Residue | AA | Distance | Residue | AA | Distance | Residue | AA | Distance | |
| (−)-Cochlactone-A | 79B | ILE | 3.85 | 286A | GLY | 1.85 | Salt Bridges | ||
| - | - | - | 286A | GLY | 2.16 | 138B | ARG | 4.45 | |
| 131B | PRO | 3.53 | 297A | ARG | 3.13 | 141B | HIS | 5.14 | |
| - | - | - | - | - | - | - | - | - | |
| 285A | ALA | 3.42 | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | |
| Phelligridin-C | 79B | ILE | 3.92 | 83B | ARG | 3.27 | π–Cation Interactions | ||
| 125B | TYR | 3.72 | 142B | GLN | 2.55 | 83B | ARG | 4.97 | |
| - | - | - | 286A | GLY | 1.92 | ||||
| 131B | PRO | 3.83 | 290A | GLN | 2.5 | Salt Bridges | |||
| 285A | ALA | 3.29 | 297A | ARG | 2.2 | 138B | ARG | 4.1 | |
| Sterenin-E | 79B | ILE | 3.43 | 83B | ARG | 3.09 | π–Cation Interactions | ||
| 82B | TYR | 3.52 | 141B | HIS | 2.69 | 83B | ARG | 5.19 | |
| - | - | - | 142B | GLN | 2.72 | Salt Bridges | |||
| - | - | - | 142B | GLN | 2.66 | 138B | ARG | 4.74 | |
| 293A | LEU | 3.38 | 287A | ASN | 2.55 | 141B | HIS | 5.08 | |
| - | - | - | 290A | GLN | 2.66 | - | - | - | |
| - | - | - | 297A | ARG | 3.36 | - | - | - | |
| Cyathusal-A | 79B | ILE | 3.73 | 83B | ARG | 3.15 | π–Cation Interactions | ||
| - | - | - | 138B | ARG | 2.37 | 83B | ARG | 5.11 | |
| 285A | ALA | 3.92 | 142B | GLN | 2.51 | - | - | - | |
| - | - | - | 290A | GLN | 2.5 | - | - | - | |
| - | - | - | 297A | ARG | 2.45 | - | - | - | |
Figure 4Interaction profile of screened ligands with Eg5 protein: (a) (-)-Cochlactone A, (b) Phelligridin-C, (c) Sterenin E, and (d) Cyathusal A.
Figure 5Curves illustrating the behavior of the interactions of screened compounds with EG5 protein in the form of Rg, RMSF, and RMSD during MD simulation.